

---

# List Of Contents

Items	No of page
<b>Introduction</b> .....	1
<b>Aim of work</b> .....	3
<b>Review of literature:</b>	
□ Pulmonary hypertension	4
□ SILDENAFIL: A HIGHLY SELECTIVE PDE5 INHIBITOR	46
□ Use of sildenafil citrate in patients with cardiovascular disease.	
□ Phosphodiesterase type 5 Inhibitor for Pulmonary Arterial Hypertension	57
	70
<b>Patients &amp; Methods</b> .....	77
<b>Results</b> .....	81
<b>Discussion</b> .....	111
<b>Conclusion, recommendation and limitations</b> .....	122
<b>Summary</b> .....	123
<b>References</b> .....	125

---

## List Of Tables

Table No.	Title	Page
1	Updated clinical classification of pulmonaryhypertension	6
2	Functional classification of pulmonary hypertension modified after the NYHA according to the WHO.	27
3	Agents for Vasodilator Testing	30
4	Baseline charachristic	82
5	Haemodynamic parameters after six weeks.	83
6	Etiology of pulmonary hypertension	84
7	Echocardiographic data at base line and after six weeks on sildenafil and placebo group	86
8	NYHA changes from baseline to six weeks.	89
9	Haemodynamic,echocardiographic and functional parameters in patients with pulmonary hypertension secondary to valvular disease.	92
10	Haemodynamic,echocardiographic and functional parameters in patients with pulmonary hypertension secondary to thromboembolic disease.	96
11	Haemodynamic,echocardiographic and functional parameters in patients with pulmonary hypertension secondary toIPF.	100
	Haemodynamic,echocardiographic and functional	104

---

12	parameters in patients with pulmonary hypertension secondary to COPD	
13	Haemodynamic, echocardiographic and functional parameters in patients with pulmonary hypertension secondary to non IDCM .	108

---

## List Of Figures

<b>Fig No.</b>	<b>Title</b>	<b>Page</b>
1	Three major mechanistic pathways are known to be perturbed in patients with PAH	15
2	Chest radiography, ECG and Doppler echocardiogram in PAH	26
a,b,c		
3	Algorithm for the medical treatment of PAH..	45
4	Chemical structure of sildenafil.	48
5	Mechanism of action of sildenafil. NOS, nitric oxide synthase; K , potassium; Ca , calcium..	49
6	Rationale for sildenafil use in pulmonary arterial hypertension. GC, guanylate cyclase; GTP, guanosine triphosphate.	54
7	Haemodynamic parameters at baseline and after 6 weeks.	83
8	PASP at baseline and after 6 weeks on sildenafil and placebo groups .	87
9	Ejection fraction % at baseline and after 6 weeks on sildenafil and placebo group.	87
10	Mean N Y H A class at baseline and after 6 weeks on sildenafil and placebo groups.	90
11	Haemodynamic and echocardiographic parameters at baseline to 6 weeks(valvular group.)	93
12	Functionl class at six weeks (valvular group.)	94

---

13	Haemodynamic and echocardiographic parameters at baseline to 6 weeks(thromboembolic)	97
14	Functionl class at six weeks(thromboembolic)	97
15	Haemodynamic and echocardiographic parameters at baseline to 6 weeks(I P F).	101
16	Functionl class at six weeks (I P F).	102
17	Haemodynamic and echocardiographic parameters at baseline to 6 weeks(C O P D).	105
18	Functionl class at six weeks (C O P D).	106
19	Haemodynamic and echocardiographic parameters at baseline to 6 weeks(non I D C M).	109
20	Functionl class at six weeks (non I D C M).	110

---

## List Of Abbreviations

COPD	: Chronic obstructive pulmonary disease.
ECG	: Elctrocardiogram.
EF	: Ejection fraction.
FPAH	: Familial pulmonary arterial hypertension.
HIV	: Human immunodeficiency virus.
IPF	: Interstitial pulmonary fibrosis.
LVEDD	: Left ventricular End diastolic dimension.
LVESD	: Left ventricular End systolic dimension.
LVH	: Left ventricular hypertrophy .
LVRS	: Lung volume reduction surgery.
NO	: Nitric oxide.
PAH	: Pulmonary arterial hypertension.
PASP	: Pulmonary artery systolic pressure.
PHT	: Pulmonary hypertension.
Ppcw	: Pulmonary Capillary wedge pressure.
PPH	: Primary pulmonary hypertension.
PT	: Prothrombin Time.
PVR	: Pulmonary vascular resistance.
RVDD	: Right ventricular Diastolic dimension .
RVEF	: Right Ventricular ejection fraction.
TDI	: Tissue Doppler Imaging.
TGF	: Transforming growth factor.
TR	: Tricuspid regurge
WHO	: World Health Organization.

